title: Surgical resection and radiotherapy for primary retroperitoneal soft tissue sarcoma.
abstract: METHODS
  Forty-five patients were consecutively treated for primary retroperitoneal soft tissue sarcoma with surgery in combination with radiation therapy in the same institution. The median follow-up time was 53 months (7-108).
  
  
  RESULTS
  Seventeen (38%) patients had clear microscopic margins (R0 resection), 26 patients (58%) had gross complete surgical excision (R1 resection) and two patients (4%) had a macroscopic residual disease (R2 resection). External radiotherapy doses ranged from 40.8 to 59.4 Gy (mean and median: 49 Gy). Seventeen patients underwent intraoperative radiation therapy (IORT). Moreover, 11 patients received chemotherapy. The overall 1-, 2-, and 5-year survival for all 45 patients were 93, 85 and 60%, respectively. The 1-, 2-, and 5-year locoregional relapse-free rate for the whole group was 91, 70 and 40%, respectively. In univariate analysis, quality of surgery was the only variable to show a significant effect for overall survival (P=0.0386) and for local control (P=0.0059). Tumor size and tumor grade had no statistically significant effect. For the patients receiving IORT+external beam radiation therapy, no difference was observed for survival or locoregional control. The most frequent acute side effects treatment complications were radiation-induced nausea or vomiting (42%) and moderate enteritis (30%). Significant late morbidity was observed for two patients.
  
  
  CONCLUSIONS
  This study confirms the feasibility of external postoperative radiotherapy with an acceptable level of toxicity. However, the high rate of local relapses (especially in field of radiation) does not demonstrate the usefulness of radiotherapy at the level of dose used and further preferably randomized studies should be planned.
authors.affiliation: Radiation Oncology Department, Institut Bergonié, Regional Cancer Center, 229, cours de l'Argonne, 33076 Bordeaux, France.
authors.forename: Laurent
authors.initials: L
authors.lastname: Gilbeau
authors.forename: Guy
authors.initials: G
authors.lastname: Kantor
authors.forename: Eberhard
authors.initials: E
authors.lastname: Stoeckle
authors.forename: Philippe
authors.initials: P
authors.lastname: Lagarde
authors.forename: Laurence
authors.initials: L
authors.lastname: Thomas
authors.forename: Michèle
authors.initials: M
authors.lastname: Kind
authors.forename: Pierre
authors.initials: P
authors.lastname: Richaud
authors.forename: Jean-Michel
authors.initials: JM
authors.lastname: Coindre
authors.forename: Françoise
authors.initials: F
authors.lastname: Bonichon
authors.forename: Binh Nguyen
authors.initials: BN
authors.lastname: Bui
mesh_terms: D000328:Adult; D000368:Aged; D001707:Biopsy, Needle; D015331:Cohort Studies; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D015994:Incidence; D007813:Laparotomy / Q000379:methods; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology / Q000473:pathology*; D009367:Neoplasm Staging; D010534:Peritoneal Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery*; D011336:Probability; D011379:Prognosis; D011879:Radiotherapy Dosage; D018714:Radiotherapy, Adjuvant / Q000379:methods; D012187:Retroperitoneal Space; D012189:Retrospective Studies; D018570:Risk Assessment; D012509:Sarcoma / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery*; D016019:Survival Analysis; D016896:Treatment Outcome